Ftse Mib
33.962,38
-0,97%
DAX
18.000,85
-0,72%
S&P 500
5.116,17
0,00%
NASDAQ Composite
15.983,08
0,00%
Bitcoin
61.157,97
-4,20%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Cumberland Pharmaceutical Inc (CPIX) Cumberland Pharmaceutical Inc (CPIX) Notizie

Cumberland Pharmaceutical Inc

CPIX
1,695
0,00 (0,00%)
Pre Mercato
Ultimo aggiornamento: 13:00:11
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
02/4/202422:05PRNUSNEW REPORT SUPPORTS USE OF CALDOLOR® AS A STANDARD OF CARE..
05/3/202423:10EDGAR2Form 8-K - Current report
05/3/202422:05PRNUSCumberland Pharmaceuticals Reports Annual 2023 Financial..
27/2/202422:05PRNUSCUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2023 FINANCIAL..
09/2/202423:27EDGAR2Form SC 13G - Statement of acquisition of beneficial..
28/12/202323:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/12/202323:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/12/202323:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/12/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
15/12/202322:14EDGAR2Form DEL AM - Delaying amendment
14/12/202323:09EDGAR2Form S-3 - Registration statement under Securities Act of..
06/12/202323:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/12/202323:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/12/202323:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/11/202323:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/11/202323:21EDGAR2Form 8-K - Current report
07/11/202322:05PRNUSCumberland Pharmaceuticals Reports Third Quarter 2023..
03/11/202322:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/11/202322:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/11/202322:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/10/202321:05PRNUSCUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2023..
17/10/202323:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/10/202315:11EDGAR2Form 8-K - Current report
10/10/202322:05PRNUSNEW VIBATV® PEDIATRIC PUBLICATION HIGHLIGHTS ITS SAFETY IN..
03/10/202323:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/10/202323:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/10/202323:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/9/202316:55DJNCorrection to SEC Fines Article
27/9/202316:43DJNSEC Fines 5 Public Companies, Insiders Over Reporting..
19/9/202315:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/9/202323:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/9/202323:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/9/202323:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/8/202323:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202323:23EDGAR2Form 8-K - Current report
08/8/202322:05PRNUSCumberland Pharmaceuticals Reports Revenue and Earnings..
01/8/202322:05PRNUSCUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2023..
30/6/202323:20EDGAR2Form 8-K - Current report
26/6/202315:00PRNUSNEW PUBLICATION SUPPORTS THE USE OF CALDOLOR® IN NEWBORN..
23/5/202315:00PRNUSCUMBERLAND PHARMACEUTICALS ANNOUNCES FDA CLEARANCE OF IND..
15/5/202315:00PRNUSCALDOLOR® NOW FDA APPROVED FOR TREATMENT OF FEVER & PAIN IN..
09/5/202322:05PRNUSCumberland Pharmaceuticals Reports First Quarter 2023..
02/5/202322:05PRNUSCUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2023..
Apertura: Min: Max:
Chiusura: 1,695

La tua Cronologia

NASDAQ
CPIX
Cumberland Pharmaceutical
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network